• Mallinckrodt Inc., of St. Louis, said the FDA extended the review of the new drug application (NDA) for Xartemis XR (oxycodone hydrochloride and acetaminophen) extended-release tablets, previously known as MNK-795, for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.